Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of NNC0385-0434 Formulations in Healthy Men
NCT05333107Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NNC0385-0434 in hypercholesterolemia (6 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from 0 to 24 hours. Started Apr 2022; status: completed.
02
Drugs
NNC0385-0434
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05333107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333107.